Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
IBM Watson Health and the U.S. Food and Drug Administration (FDA) have joined together in a research initiative to determine if blockchain technology can be used as a secure patient data sharing platform.
Researchers can agree that the Global Initiative on Sharing All Influenza Data (GISAID) shows just how possible it is for improved international sharing of data that could protect people in the event of a deadly infectious disease outbreak.
Scientists from Rutgers University have discovered a molecular pathway that could help develop drug therapies to prevent dementia. It could also provide new insights into memory degradation in the elderly.
Primary care doctors in rural parts of New Jersey are receiving education and training from specialists via “tele-monitoring” clinics so patients don’t have to travel long distances to get a specialist’s care.
People who had gone three years or more without having health insurance made up more than half of the gains in coverage in 2014, the first year of the Affordable Care Act (ACA)’s insurance marketplace and Medicaid expansion.
Yiling Pharmaceuticals, a technology company in China, is investing $20 million in HealthWatch, an Israeli company that makes medical-grade smart clothing.
Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more.
Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.
When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country.